Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiac failure with normal ejection fraction: possible role of phosphodiesterase type 5 inhibitors
2007-004150-85Phase 2Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of vardenafil in heart failure with preserved ejection fraction (HFpEF), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Improvement of cardiac insufficiency symptoms. Started Dec 2007; status: terminated.
02
Drugs
vardenafil
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on 2007-004150-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004150-85.